ME03426B - Trifluorometil alkoholi kao modulatori ror-gama-t - Google Patents

Trifluorometil alkoholi kao modulatori ror-gama-t

Info

Publication number
ME03426B
ME03426B MEP-2019-118A MEP2019118A ME03426B ME 03426 B ME03426 B ME 03426B ME P2019118 A MEP2019118 A ME P2019118A ME 03426 B ME03426 B ME 03426B
Authority
ME
Montenegro
Prior art keywords
ror
modulators
gamma
trifluoromethyl alcohols
trifluoromethyl
Prior art date
Application number
MEP-2019-118A
Other languages
German (de)
English (en)
French (fr)
Inventor
Xiaohua Xue
Christoph Steeneck
Christian Gege
Olaf Kinzel
Gerald Kleymann
Thomas Hoffmann
Steven Goldberg
Hariharan Venkatesan
Virginia Tanis
Anne M Fourie
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54754732&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ME03426(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of ME03426B publication Critical patent/ME03426B/me

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/10—Spiro-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Otolaryngology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
MEP-2019-118A 2014-10-30 2015-10-30 Trifluorometil alkoholi kao modulatori ror-gama-t ME03426B (me)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462072563P 2014-10-30 2014-10-30
EP15802227.7A EP3212643B1 (en) 2014-10-30 2015-10-30 Trifluoromethyl alcohols as modulators of ror-gamma-t
PCT/US2015/058193 WO2016069974A1 (en) 2014-10-30 2015-10-30 TRIFLUOROMETHYL ALCOHOLS AS MODULATORS OF RORyt

Publications (1)

Publication Number Publication Date
ME03426B true ME03426B (me) 2020-01-20

Family

ID=54754732

Family Applications (1)

Application Number Title Priority Date Filing Date
MEP-2019-118A ME03426B (me) 2014-10-30 2015-10-30 Trifluorometil alkoholi kao modulatori ror-gama-t

Country Status (40)

Country Link
US (2) US9850236B2 (me)
EP (2) EP3212643B1 (me)
JP (3) JP6998204B2 (me)
KR (2) KR20170078750A (me)
CN (3) CN112979630A (me)
AR (2) AR102480A1 (me)
AU (2) AU2015339087B2 (me)
BR (2) BR112017008816A2 (me)
CA (1) CA2965512C (me)
CL (3) CL2017001042A1 (me)
CO (1) CO2017005014A2 (me)
CR (2) CR20170542A (me)
CY (1) CY1121716T1 (me)
DK (1) DK3212643T3 (me)
EA (2) EA035998B1 (me)
EC (1) ECSP17033054A (me)
ES (2) ES2858503T3 (me)
GT (1) GT201700090A (me)
HR (1) HRP20190900T1 (me)
HU (1) HUE043624T2 (me)
IL (2) IL251865A0 (me)
JO (2) JO3571B1 (me)
LT (1) LT3212643T (me)
MA (1) MA40873B1 (me)
ME (1) ME03426B (me)
MX (2) MX369567B (me)
PE (2) PE20180250A1 (me)
PH (2) PH12017500800B1 (me)
PL (1) PL3212643T3 (me)
PT (1) PT3212643T (me)
RS (1) RS58613B1 (me)
SG (2) SG11201703323PA (me)
SI (1) SI3212643T1 (me)
SM (1) SMT201900290T1 (me)
SV (1) SV2017005429A (me)
TR (1) TR201907763T4 (me)
TW (2) TWI705057B (me)
UY (2) UY36377A (me)
WO (1) WO2016069974A1 (me)
ZA (3) ZA201703679B (me)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201803869A (zh) * 2016-04-27 2018-02-01 健生藥品公司 作為ＲＯＲγＴ調節劑之６－胺基吡啶－３－基噻唑
EP3765009A4 (en) * 2018-03-12 2021-11-10 Escalier Biosciences, BV BICYCLIC ROR-GAMMA MODULATORS
KR20210060367A (ko) 2018-03-12 2021-05-26 에스칼리에 바이오사이언시스, 비브이 스피로사이클릭 ror-감마 조절제
JP2021528405A (ja) 2018-06-18 2021-10-21 ヤンセン ファーマシューティカ エヌ．ベー． ＲＯＲγｔのモジュレータとしてのアミド置換チアゾール
JP2021528398A (ja) 2018-06-18 2021-10-21 ヤンセン ファーマシューティカ エヌ．ベー． ＲＯＲγＴのモジュレーターとしての６−アミノピリジン−３−イルピラゾール
ES2929140T3 (es) * 2018-06-18 2022-11-25 Janssen Pharmaceutica Nv Imidazoles sustituidos con fenilo y piridinilo como moduladores de RORgammat
EP3807261B1 (en) 2018-06-18 2022-07-13 Janssen Pharmaceutica NV Pyridinyl pyrazoles as modulators of roryt
WO2023232870A1 (en) 2022-05-31 2023-12-07 Immunic Ag Rorg/rorgt modulators for the treatment of virus infections like covid-19
WO2024089216A1 (en) 2022-10-27 2024-05-02 Syngenta Crop Protection Ag Novel sulfur-containing heteroaryl carboxamide compounds
CN119528866B (zh) * 2024-11-28 2025-10-17 河南农业大学 一种含双三氟甲基的香豆素叔醇类化合物及其制备方法和应用

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL91418A (en) 1988-09-01 1997-11-20 Rhone Poulenc Agrochimie (hetero) cyclic amide derivatives, process for their preparation and fungicidal compositions containing them
AU3201095A (en) 1994-07-27 1996-02-22 G.D. Searle & Co. Substituted thiazoles for the treatment of inflammation
CZ20032829A3 (cs) 2001-04-16 2005-03-16 Tanabe Seiyaku Co., Ltd. Heterocyklické sloučeniny
ATE325608T1 (de) 2001-08-13 2006-06-15 Janssen Pharmaceutica Nv 2,4,5-trisubstituted thiazolyl derivative und deren antiinflammatorische wirkung
TWI336697B (en) * 2003-09-19 2011-02-01 Solvay Pharm Bv Thiazole derivatives as cannabinoid receptor modulators
WO2006124687A1 (en) 2005-05-12 2006-11-23 University Of Medicine And Dentistry Of New Jersey Opioid receptor subtype-selective agents
GB0518237D0 (en) * 2005-09-07 2005-10-19 Angeletti P Ist Richerche Bio Therapeutic compounds
US8455658B2 (en) 2006-01-25 2013-06-04 Synta Pharmaceuticals Corp. Thiazole and thiadiazole compounds for inflammation and immune-related uses
WO2008064317A1 (en) 2006-11-22 2008-05-29 University Of Medicine And Dentistry Of New Jersey Lipophilic opioid receptor active compounds
WO2008064318A2 (en) 2006-11-22 2008-05-29 University Of Medicine And Dentistry Of New Jersey Peripheral opioid receptor active compounds
WO2009011850A2 (en) 2007-07-16 2009-01-22 Abbott Laboratories Novel therapeutic compounds
EP2583556B1 (de) 2008-07-17 2016-01-20 Bayer CropScience AG Heterocyclische Verbindungen als Schädlingsbekämpfungsmittel
WO2010118078A1 (en) * 2009-04-08 2010-10-14 Idenix Pharmaceuticals, Inc. Macrocyclic serine protease inhibitors
AR079022A1 (es) 2009-11-02 2011-12-21 Sanofi Aventis Derivados de acido carboxilico ciclico sustituidos con acilamino, su uso como productos farmaceuticos, composicion farmaceutica y metodo de preparacion
EP2368886A1 (en) * 2010-03-01 2011-09-28 Phenex Pharmaceuticals AG Novel compounds for modulation of orphan nuclear receptor RAR-related orphan receptor-gamma (ROR gamma, NR1F3) activity and for the treatment of chronic inflammatory and autoimmune desease
US9101600B2 (en) 2010-03-11 2015-08-11 New York University Compounds as RORγt modulators and uses thereof
WO2011112263A1 (en) 2010-03-11 2011-09-15 New York University AMIDO COMPOUNDS AS RORγt MODULATORS AND USES THEREOF
WO2011115892A1 (en) 2010-03-15 2011-09-22 Griffin Patrick R Modulators of the retinoic acid receptor-related orphan receptors
WO2012027965A1 (en) 2010-09-01 2012-03-08 Glaxo Group Limited Novel compounds
WO2012074547A2 (en) 2010-11-29 2012-06-07 New York University STEROID COMPOUNDS AS RORγt MODULATORS AND USES THEREOF
KR101958699B1 (ko) 2010-12-28 2019-03-15 라이온 가부시키가이샤 구강 상태의 판정 방법, 그리고 그것을 위해 사용되는 분석 용구, 장치, 및 프로그램
US9012651B2 (en) 2011-03-24 2015-04-21 Abbvie Inc. TRPV3 modulators
WO2012158784A2 (en) 2011-05-16 2012-11-22 Theodore Mark Kamenecka Modulators of the nuclear hormone receptor ror
WO2013018695A1 (ja) 2011-07-29 2013-02-07 武田薬品工業株式会社 複素環化合物
SG11201400456RA (en) 2011-09-09 2014-04-28 Univ New York Amido compounds as ror?tmodulators and uses thereof
GB201116641D0 (en) * 2011-09-27 2011-11-09 Glaxo Group Ltd Novel compounds
EP2800745B1 (en) 2011-12-02 2020-02-12 Phenex Pharmaceuticals AG Pyrrolo carboxamides as modulators of orphan nuclear receptor rar-related orphan receptor-gamma (rory, nr1f3) activity and for the treatment of chronic inflammatory and autoimmune diseases
US20130190356A1 (en) 2011-12-22 2013-07-25 Genentech, Inc. Benzyl sulfonamide derivatives as rorc modulators
SG11201407919WA (en) * 2012-05-31 2014-12-30 Phenex Pharmaceuticals Ag Carboxamide or sulfonamide substituted thiazoles and related derivatives as modulators for the orphan nuclear receptor ror[gamma]
JO3215B1 (ar) 2012-08-09 2018-03-08 Phenex Pharmaceuticals Ag حلقات غير متجانسة بها 5 ذرات تحتوي على النيتروجين بها استبدال بكربوكساميد أو سلفوناميد كمعدلات لمستقبل نووي غير محمي RORy
CN105073729A (zh) * 2012-10-16 2015-11-18 詹森药业有限公司 RORγt的苯基连接的喹啉基调节剂
EP2931281B1 (en) * 2012-12-12 2018-01-17 Merck Sharp & Dohme Corp. Amino-pyrimidine-containing spleen tyrosine kinase inhibitors
US9611254B2 (en) 2013-06-04 2017-04-04 Acturum Life Science AB Triazole compounds and their use as gamma secretase modulators
CN103333168B (zh) * 2013-07-23 2015-08-05 清华大学 一种酰胺类化合物及其制备方法与应用
JP6407285B2 (ja) 2013-09-09 2018-10-17 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ ＲＯＲγ調節因子
US20150072890A1 (en) 2013-09-11 2015-03-12 20/20 Gene Systems, Inc. Methods and compositions for aiding in the detection of lung cancer
JP6397488B2 (ja) 2013-09-20 2018-09-26 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ ＲＯＲγ調節因子
JP6320523B2 (ja) * 2013-10-15 2018-05-09 ヤンセン ファーマシューティカ エヌ．ベー． ＲＯＲγＴの第二級アルコールキノリニルモジュレータ
BR112016008215A2 (pt) * 2013-10-15 2017-09-26 Janssen Pharmaceutica Nv moduladores de quinolinila ligados por alquila de roryt
WO2015082533A1 (en) 2013-12-05 2015-06-11 Lead Pharma Cel Models Ip B.V. Ror gamma (rory) modulators
JP6476205B2 (ja) 2014-01-06 2019-02-27 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ ＲＯＲγ修飾因子としてのヘテロ環式スルホン
ES2704460T3 (es) 2014-01-06 2019-03-18 Bristol Myers Squibb Co Moduladores de ROR gamma de ciclohexilsulfona
EA030849B1 (ru) 2014-01-06 2018-10-31 Бристол-Маерс Сквибб Компани ПИРРОЛИДИНИЛСУЛЬФОНОВЫЕ МОДУЛЯТОРЫ RORγ
WO2015103508A1 (en) 2014-01-06 2015-07-09 Bristol-Myers Squibb Company CARBOCYCLIC SULFONE RORγ MODULATORS
WO2015145371A1 (en) 2014-03-27 2015-10-01 Piramal Enterprises Limited Ror-gamma modulators and uses thereof
EP3212641B1 (en) 2014-10-30 2018-12-05 Janssen Pharmaceutica NV Thiazoles as modulators of roryt
HRP20200016T1 (hr) 2014-10-30 2020-03-20 Janssen Pharmaceutica Nv Amidno supstituirani tiazoli kao modulatori rorgamat

Also Published As

Publication number Publication date
CA2965512C (en) 2020-03-10
RS58613B1 (sr) 2019-05-31
ES2724556T3 (es) 2019-09-12
KR20170078750A (ko) 2017-07-07
MX369567B (es) 2019-11-12
TW201629027A (zh) 2016-08-16
ECSP17033054A (es) 2018-01-31
UY36377A (es) 2016-04-29
JP6623270B2 (ja) 2019-12-18
IL255648A (en) 2018-01-31
PE20180250A1 (es) 2018-02-02
CL2019001514A1 (es) 2019-10-04
IL255648B (en) 2020-06-30
UY37517A (es) 2018-01-31
TW201927759A (zh) 2019-07-16
CR20170166A (es) 2017-08-22
CN112979630A (zh) 2021-06-18
AU2019200228A1 (en) 2019-01-31
AR102480A1 (es) 2017-03-01
BR122017023050A2 (pt) 2019-09-10
WO2016069974A1 (en) 2016-05-06
US9850236B2 (en) 2017-12-26
PH12017500800A1 (en) 2017-10-02
PT3212643T (pt) 2019-06-17
PH12017500800B1 (en) 2017-10-02
EP3212643A1 (en) 2017-09-06
PL3212643T3 (pl) 2019-08-30
HK1258212A1 (en) 2019-11-08
JP2020180129A (ja) 2020-11-05
US20160122336A1 (en) 2016-05-05
ZA201805860B (en) 2019-11-27
CA2965512A1 (en) 2016-05-06
EP3354651B1 (en) 2021-01-06
EA035998B1 (ru) 2020-09-10
US10150762B2 (en) 2018-12-11
MX367912B (es) 2019-09-11
HUE043624T2 (hu) 2019-08-28
BR112017008816A2 (pt) 2017-12-19
EP3212643B1 (en) 2019-03-20
AU2015339087A1 (en) 2017-05-11
MA40873A (fr) 2017-09-05
SV2017005429A (es) 2017-10-17
SMT201900290T1 (it) 2019-07-11
PE20171649A1 (es) 2017-11-13
CL2018000436A1 (es) 2018-07-06
ZA201703679B (en) 2019-06-26
CR20170542A (es) 2018-02-20
TWI667230B (zh) 2019-08-01
AU2019200228B2 (en) 2020-04-16
AR110155A2 (es) 2019-02-27
CN107108599A (zh) 2017-08-29
CO2017005014A2 (es) 2017-08-31
KR20170127580A (ko) 2017-11-21
EA033699B1 (ru) 2019-11-18
TR201907763T4 (tr) 2019-06-21
ZA201805861B (en) 2019-11-27
DK3212643T3 (da) 2019-05-13
JOP20200117A1 (ar) 2020-05-18
JP2019059728A (ja) 2019-04-18
HRP20190900T1 (hr) 2019-07-12
CY1121716T1 (el) 2020-07-31
JP2018500287A (ja) 2018-01-11
SG11201703323PA (en) 2017-05-30
EP3354651A1 (en) 2018-08-01
SI3212643T1 (sl) 2019-04-30
SG10201805355YA (en) 2018-07-30
IL251865A0 (en) 2017-06-29
TWI705057B (zh) 2020-09-21
MX2017005689A (es) 2018-02-19
EA201790942A1 (ru) 2017-09-29
CN107827841A (zh) 2018-03-23
US20170327492A1 (en) 2017-11-16
GT201700090A (es) 2019-08-08
MA40873B1 (fr) 2019-07-31
JO3571B1 (ar) 2020-07-05
ES2858503T3 (es) 2021-09-30
PH12017502105A1 (en) 2019-11-25
JP6998204B2 (ja) 2022-02-04
EA201891562A2 (ru) 2018-12-28
CL2017001042A1 (es) 2017-12-01
AU2015339087B2 (en) 2020-01-23
EA201891562A3 (ru) 2019-04-30
LT3212643T (lt) 2019-06-10

Similar Documents

Publication Publication Date Title
IL259421B (en) ror - gamma modulators
SG11201609265RA (en) Characterizing states of subject
ZA201705060B (en) Use of picolinamides as fungicides
PL3218005T3 (pl) Związki oddziałujące z glikanami i sposoby ich zastosowania
SI3089971T1 (sl) Spojine in postopki za uporabo
ZA201805861B (en) TRIFLUOROMETHYL ALCOHOLS AS MODULATORS OF RORyt
SI3845221T1 (sl) Trdne oblike sofosbuvirja
IL246979A0 (en) Crystalline forms of sofosbuvir
IL249130A0 (en) Preparation of piperidine-4-carbthioamide
IL247234A0 (en) Caspase-6 modulators
GB201412010D0 (en) Treatment of hypertransaminasemia
SG11201607445QA (en) Methods of modulating wars2
GB201403697D0 (en) Compounds and methods of use
TWM476518U (en) Backplate of backpack
IL249332A0 (en) Crystalline forms of sofosbuvir
TWM489666U (en) Structure of goggles
GB201418230D0 (en) Construction of surfaces
GB201406276D0 (en) Making of land
GB201405154D0 (en) Theory of hairdressing
GB201417348D0 (en) Prodrugs of lxazomib
GB201417347D0 (en) Prodrugs of delanzomib
HUP1400294A2 (hu) Clopidogrel új alkalmazása
GB201413139D0 (en) Assessment of structures
GB201413138D0 (en) Assessment of structures
GB201400215D0 (en) Modulators